Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
…, SA Strickland, R Tibes, C Ustun, ES Wang… - The Lancet …, 2017 - thelancet.com
Background Internal tandem duplication mutations in FLT3 are common in acute myeloid
leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit …
leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit …
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
…, ES Wang, MR Baer, A Perl, S Coutre… - Blood, The Journal …, 2011 - ashpublications.org
In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid
leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of …
leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of …
Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology
MS Tallman, ES Wang, JK Altman… - Journal of the National …, 2019 - jnccn.org
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States. …
and accounts for the largest number of annual deaths due to leukemias in the United States. …
Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology
…, PJ Shami, RM Stone, SA Strickland, ES Wang… - Journal of the National …, 2017 - jnccn.org
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States. …
and accounts for the largest number of annual deaths due to leukemias in the United States. …
[HTML][HTML] Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm
…, S Vasu, W Blum, DA Rizzieri, ES Wang… - … England Journal of …, 2019 - Mass Medical Soc
Background Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress …
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress …
Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - Cancer discovery, 2019 - AACR
Comprehensive serial genotyping of AML specimens from patients treated with the selective
FLT3 inhibitor gilteritinib demonstrates that complex, heterogeneous patterns of clonal …
FLT3 inhibitor gilteritinib demonstrates that complex, heterogeneous patterns of clonal …
Acute myeloid leukemia
…, SA Strickland, MS Tallman, ES Wang… - Journal of the National …, 2012 - jnccn.org
Acute myeloid leukemia (AML) remains the most common form of acute leukemia among
adults and accounts for the largest number of annual deaths due to leukemias in the United …
adults and accounts for the largest number of annual deaths due to leukemias in the United …
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes …
Purpose Although azacitidine (AZA) improves survival in patients with high-risk myelodysplastic
syndrome, the overall response remains approximately 50%. Entinostat is a histone …
syndrome, the overall response remains approximately 50%. Entinostat is a histone …
[HTML][HTML] Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
…, JB Micol, JP De Oteyza, F Thol, ES Wang… - Leukemia, 2021 - nature.com
We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing
Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 …
Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 …
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
…, N Russell, NP Shah, CC Smith, ES Wang… - The Lancet …, 2018 - thelancet.com
Background Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)
mutations in patients with acute myeloid leukaemia are associated with early relapse and …
mutations in patients with acute myeloid leukaemia are associated with early relapse and …